Cargando…
Diagnosis and phenotypic assessment of trimethylaminuria, and its treatment with riboflavin: (1)H NMR spectroscopy and genetic testing
BACKGROUND: Trimethylaminuria (TMAU) is a metabolic disorder characterized by the excessive excretion of the malodorous compound trimethylamine (TMA). The diagnosis of TMAU is challenging because this disorder is situated at the boundary between biochemistry and psychiatry. Here, we used nuclear mag...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751875/ https://www.ncbi.nlm.nih.gov/pubmed/31533761 http://dx.doi.org/10.1186/s13023-019-1174-6 |
_version_ | 1783452703680102400 |
---|---|
author | Bouchemal, Nadia Ouss, Lisa Brassier, Anaïs Barbier, Valérie Gobin, Stéphanie Hubert, Laurence de Lonlay, Pascale Le Moyec, Laurence |
author_facet | Bouchemal, Nadia Ouss, Lisa Brassier, Anaïs Barbier, Valérie Gobin, Stéphanie Hubert, Laurence de Lonlay, Pascale Le Moyec, Laurence |
author_sort | Bouchemal, Nadia |
collection | PubMed |
description | BACKGROUND: Trimethylaminuria (TMAU) is a metabolic disorder characterized by the excessive excretion of the malodorous compound trimethylamine (TMA). The diagnosis of TMAU is challenging because this disorder is situated at the boundary between biochemistry and psychiatry. Here, we used nuclear magnetic resonance spectroscopy to assess TMAU in 13 patients. We also sequenced the FMO3 gene in 11 of these patients. Treatment with vitamin B2 was prescribed. RESULTS: Two patients (aged 3 and 9 years at the initial consultation) had a particularly unpleasant body odor, as assessed by their parents and the attending physicians. The presence of high urine TMA levels confirmed the presence of a metabolic disorder. The two (unrelated) children carried compound heterozygous variants in the FMO3 gene. In both cases, vitamin B2 administration decreased TMA excretion and reduced body odor. The 11 adults complained of an unpleasant body odor, but the physicians did not confirm this. In all adult patients, the urine TMA level was within the normal range reported for control (non-affected) subjects, although two of the patients displayed an abnormally high proportion of oxidized TMA. Seven of the 9 tested adult patients had a hypomorphic variant of the FMO3 gene; the variant was found in the homozygous state, in the heterozygous state or combined with another hypomorphic variant. All 11 adults presented a particular psychological or psychiatric phenotype, with a subjective perception of unpleasant odor. CONCLUSIONS: The results present the clinical and biochemical data of patients complaining of unpleasant body odor. Contrary to adult patients, the two children exhibited all criteria of recessively inherited trimethylaminuria, suspected by parents in infancy. B2 vitamin treatment dramatically improved the unpleasant body odor and the ratio of TMA/Cr vs TMAO/Cr in the urine in the children. Other patients presented a particular psychological or psychiatric phenotype. |
format | Online Article Text |
id | pubmed-6751875 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-67518752019-09-23 Diagnosis and phenotypic assessment of trimethylaminuria, and its treatment with riboflavin: (1)H NMR spectroscopy and genetic testing Bouchemal, Nadia Ouss, Lisa Brassier, Anaïs Barbier, Valérie Gobin, Stéphanie Hubert, Laurence de Lonlay, Pascale Le Moyec, Laurence Orphanet J Rare Dis Research BACKGROUND: Trimethylaminuria (TMAU) is a metabolic disorder characterized by the excessive excretion of the malodorous compound trimethylamine (TMA). The diagnosis of TMAU is challenging because this disorder is situated at the boundary between biochemistry and psychiatry. Here, we used nuclear magnetic resonance spectroscopy to assess TMAU in 13 patients. We also sequenced the FMO3 gene in 11 of these patients. Treatment with vitamin B2 was prescribed. RESULTS: Two patients (aged 3 and 9 years at the initial consultation) had a particularly unpleasant body odor, as assessed by their parents and the attending physicians. The presence of high urine TMA levels confirmed the presence of a metabolic disorder. The two (unrelated) children carried compound heterozygous variants in the FMO3 gene. In both cases, vitamin B2 administration decreased TMA excretion and reduced body odor. The 11 adults complained of an unpleasant body odor, but the physicians did not confirm this. In all adult patients, the urine TMA level was within the normal range reported for control (non-affected) subjects, although two of the patients displayed an abnormally high proportion of oxidized TMA. Seven of the 9 tested adult patients had a hypomorphic variant of the FMO3 gene; the variant was found in the homozygous state, in the heterozygous state or combined with another hypomorphic variant. All 11 adults presented a particular psychological or psychiatric phenotype, with a subjective perception of unpleasant odor. CONCLUSIONS: The results present the clinical and biochemical data of patients complaining of unpleasant body odor. Contrary to adult patients, the two children exhibited all criteria of recessively inherited trimethylaminuria, suspected by parents in infancy. B2 vitamin treatment dramatically improved the unpleasant body odor and the ratio of TMA/Cr vs TMAO/Cr in the urine in the children. Other patients presented a particular psychological or psychiatric phenotype. BioMed Central 2019-09-18 /pmc/articles/PMC6751875/ /pubmed/31533761 http://dx.doi.org/10.1186/s13023-019-1174-6 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Bouchemal, Nadia Ouss, Lisa Brassier, Anaïs Barbier, Valérie Gobin, Stéphanie Hubert, Laurence de Lonlay, Pascale Le Moyec, Laurence Diagnosis and phenotypic assessment of trimethylaminuria, and its treatment with riboflavin: (1)H NMR spectroscopy and genetic testing |
title | Diagnosis and phenotypic assessment of trimethylaminuria, and its treatment with riboflavin: (1)H NMR spectroscopy and genetic testing |
title_full | Diagnosis and phenotypic assessment of trimethylaminuria, and its treatment with riboflavin: (1)H NMR spectroscopy and genetic testing |
title_fullStr | Diagnosis and phenotypic assessment of trimethylaminuria, and its treatment with riboflavin: (1)H NMR spectroscopy and genetic testing |
title_full_unstemmed | Diagnosis and phenotypic assessment of trimethylaminuria, and its treatment with riboflavin: (1)H NMR spectroscopy and genetic testing |
title_short | Diagnosis and phenotypic assessment of trimethylaminuria, and its treatment with riboflavin: (1)H NMR spectroscopy and genetic testing |
title_sort | diagnosis and phenotypic assessment of trimethylaminuria, and its treatment with riboflavin: (1)h nmr spectroscopy and genetic testing |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751875/ https://www.ncbi.nlm.nih.gov/pubmed/31533761 http://dx.doi.org/10.1186/s13023-019-1174-6 |
work_keys_str_mv | AT bouchemalnadia diagnosisandphenotypicassessmentoftrimethylaminuriaanditstreatmentwithriboflavin1hnmrspectroscopyandgenetictesting AT ousslisa diagnosisandphenotypicassessmentoftrimethylaminuriaanditstreatmentwithriboflavin1hnmrspectroscopyandgenetictesting AT brassieranais diagnosisandphenotypicassessmentoftrimethylaminuriaanditstreatmentwithriboflavin1hnmrspectroscopyandgenetictesting AT barbiervalerie diagnosisandphenotypicassessmentoftrimethylaminuriaanditstreatmentwithriboflavin1hnmrspectroscopyandgenetictesting AT gobinstephanie diagnosisandphenotypicassessmentoftrimethylaminuriaanditstreatmentwithriboflavin1hnmrspectroscopyandgenetictesting AT hubertlaurence diagnosisandphenotypicassessmentoftrimethylaminuriaanditstreatmentwithriboflavin1hnmrspectroscopyandgenetictesting AT delonlaypascale diagnosisandphenotypicassessmentoftrimethylaminuriaanditstreatmentwithriboflavin1hnmrspectroscopyandgenetictesting AT lemoyeclaurence diagnosisandphenotypicassessmentoftrimethylaminuriaanditstreatmentwithriboflavin1hnmrspectroscopyandgenetictesting |